NEW YORK (GenomeWeb News) – Vermillion has signed a cooperative research and development agreement, or CRADA, with the US Army Medical Research and Materiel Command for the evaluation of the OVA1 ovarian cancer diagnostic test, Vermillion announced today.

The project, which follows a decision by the Army to cover the OVA1 test in January 2012, will be carried out in two phases to assess the cost-benefit profile of Vermillion's test as a presurgical standard of care in women with pelvic masses and to evaluate OVA1's clinical utility in a managed care setting.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

Wired reports that 23andMe is trying to bolster its outside collaborations.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.